8-K: Haemonetics Updates CSL Plasma Rollout Timeline

Haemonetics Corporation provides an update on its supply agreement with CSL Plasma, indicating CSL expects to complete device and disposable rollout by end of 2027.

Summary

• Haemonetics Corporation (the Company) has provided an update regarding its non-exclusive supply agreement with CSL Plasma Inc. (CSL).
• CSL announced that it anticipates completing the rollout of Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables in the United States by the end of calendar year 2027.
• CSL has informed the Company that the transition is expected to occur at all of CSL's current U.S. plasma collection centers.
• The scope and timing of this rollout are subject to change and implementation details are still being determined by both CSL and Haemonetics.
• The Company is not updating its previously issued fiscal 2027 guidance at this time.
• Haemonetics expects to provide an update on the anticipated financial impact of this agreement during its second fiscal quarter earnings call in November 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update, as it confirms progress on a significant supply agreement but defers specific financial impact details.

Positives

• Confirmation of progress on the non-exclusive supply agreement with CSL Plasma Inc.
• CSL Plasma anticipates the rollout of Haemonetics' devices and disposables across all its current U.S. plasma collection centers.
• CSL Plasma expects to complete the rollout by the end of calendar year 2027, providing a clearer, albeit extended, timeline.

Negatives

• The scope and timing of the rollout remain subject to change.
• Implementation details are still to be determined by CSL and Haemonetics.
• The Company is not updating its previously issued fiscal 2027 guidance at this time, indicating uncertainty about the immediate financial impact.

Risks

• The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement.
• Actual results and the timing of certain events may differ materially from forward-looking statements due to customer demand and adoption, timing and volume of CSL purchases, changes to CSL's transition plans, and Haemonetics' ability to manufacture and supply products.
• Risks and uncertainties described in Haemonetics' other SEC filings could cause actual results to differ materially.

Future Outlook

The Company is not updating its previously issued fiscal 2027 guidance at this time. An update regarding the anticipated impact of the supply agreement on fiscal 2027 financial results is expected in November 2026 during the second fiscal quarter earnings call.

Management Comments

• CSL announced that it expects to complete the rollout of the Company's devices and disposables under the supply agreement by the end of calendar year 2027.
• CSL has informed the Company that it currently anticipates that the transition to the Company's devices and disposables will occur at all of CSL's current U.S. plasma collection centers.

Industry Context

StockSavvy.ai notes that the expansion of plasma collection center technology is a key trend, driven by increasing demand for plasma-derived therapies. Haemonetics' agreement with CSL Plasma, a major player, signifies potential market penetration for its NexSys PCS devices.

Stakeholder Impact

• Shareholders: Potential long-term revenue growth from the CSL agreement, but near-term financial impact remains uncertain.
• Employees: Continued focus on manufacturing and supply chain to meet CSL's rollout needs.
• Customers (CSL Plasma): Expected to benefit from updated technology and disposables, subject to successful implementation.
• Suppliers: Potential increased demand for components related to NexSys PCS devices and disposables.

Next Steps

• CSL Plasma to continue implementation of Haemonetics' devices and disposables.
• Haemonetics and CSL to determine implementation details for the rollout.
• Haemonetics to provide an update on the anticipated impact of the supply agreement during its second fiscal quarter earnings call in November 2026.

Key Dates

Recommendation

The filing provides an update on a significant supply agreement, confirming progress and a longer-term rollout timeline. However, the lack of immediate financial guidance updates and the acknowledgment of potential changes in scope and timing suggest a 'hold' stance until more concrete financial impacts are disclosed in November 2026.

Keywords

plasma collection, supply agreement, medical devices, disposables, plasma donation, regulatory update, financial guidance